Search

Displaying results 791 - 800 of 4692 in total
  1. Drug

    Succimer

    go.drugbank.com/drugs/DB00566
    ApprovedInvestigational

    A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.

  2. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. … Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma

  3. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.

  4. Drug

    Phosphocreatine

    go.drugbank.com/drugs/DB13191
    InvestigationalNutraceutical

    Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine.

  5. Drug

    Opium

    go.drugbank.com/drugs/DB11130
    ApprovedIllicit

    [A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies.

  6. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970] … Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.

  7. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

  8. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

  9. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. … By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and

  10. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion.